This study involves patients with gastric and pancreatic cancer who need a procedure called endoscopic ultrasound, which is a test that uses a thin tube with a camera and sound waves to look inside the digestive system and nearby organs. During this procedure, patients receive medications to help them relax and sleep, which is called deep sedation. The study will compare two different medications used for sedation: remimazolam and propofol. When remimazolam is used, the sedation will be managed by the doctor performing the endoscopy procedure, while when propofol is used, the sedation will be managed by a specialist doctor trained in anesthesia.
The purpose of the study is to compare these two sedation approaches to see which one works better and is safer during endoscopic ultrasound procedures. Patients participating in the study will be randomly assigned to receive either remimazolam or propofol for their sedation. The study will look at whether patients experience any problems with their heart or breathing during the procedure, such as low oxygen levels, changes in blood pressure, irregular heartbeat, or changes in heart rate. The medications will be given through a vein, and remimazolam can be given up to a total of 33 milligrams while propofol will be given at a rate based on the patient’s weight.
The study will also examine other aspects of the sedation experience, including how satisfied patients and doctors are with the quality of sedation, how long it takes to start the procedure, how quickly patients wake up afterward, how much time is spent in the recovery area, and whether any additional medications are needed. The study will track if patients experience pain when the medication is injected, whether they need to stay in the hospital, and whether any breathing support is required. Information will also be collected about the costs of the different sedation approaches, including the price of medications, staff time, and how long the procedure rooms are occupied.
Italy 
